---
title: "Amgen (AMGN) Gets a Buy from BMO Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285069759.md"
description: "BMO Capital analyst Evan Seigerman has maintained a Buy rating on Amgen (AMGN) with a price target of $400.00. Seigerman, who focuses on the Healthcare sector, has an average return of 7.9% and a 51.01% success rate on his stock recommendations. Amgen also received a Buy rating from Evercore ISI’s Umer Raffat on May 1, while Guggenheim maintained a Hold rating on the stock recently."
datetime: "2026-05-04T11:59:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285069759.md)
  - [en](https://longbridge.com/en/news/285069759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285069759.md)
---

# Amgen (AMGN) Gets a Buy from BMO Capital

BMO Capital analyst Evan Seigerman maintained a Buy rating on Amgen today and set a price target of $400.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Novo Nordisk. According to TipRanks, Seigerman has an average return of 7.9% and a 51.01% success rate on recommended stocks.

In addition to BMO Capital, Amgen also received a Buy from Evercore ISI’s Umer Raffat in a report issued on May 1. However, yesterday, Guggenheim maintained a Hold rating on Amgen (NASDAQ: AMGN).

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Did Amgen's Subsidiary Manipulate Data To Secure Tavneos Approval?](https://longbridge.com/en/news/284414997.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)